Navigation Links
China Medicine Corporation Awarded GSP Certification
Date:12/1/2008

GUANGZHOU, China, Dec. 1 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading developer and distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations today announced that the Company was awarded GSP (Good Supply Practice for Pharmaceutical Products) certification from the Guangdong Food and Drug Administration (Guangdong FDA).

The GSP certification is given to pharmaceutical distributors that meet with the designated quality control systems required by the Guangdong FDA, which evaluates the management of employees, facility, inventory, sales and distribution systems, as well as product management systems. A stringent quality control system is required by the Chinese government to protect the integrity of the pharmaceutical industry in China as distributors are mandated to be GSP certified in order to engage in the pharmaceutical distribution business in China.

In conjunction with China Medicine's success in obtaining the GSP certification, the Company will also be considered by the Guangdong FDA to include dentistry medical devices and instruments, peptide praeparatum and protein anabolica in its distribution product offering. The Company expects to receive the official approval in approximately 7 days for the aforementioned products.

"We are honored to have received the GSP certification and we will continue to promote and improve our quality control system to ensure the safety of the pharmaceutical products we distribute to the public," said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. "Recently, we moved our warehouse to one that is double the size of the previous warehouse and is well furnished with state-of-the-art equipment, which includes a refrigeration storage facility. We are confident that our continuous commitment to high-standard quality control systems will further solidify our position as a leading developer and distributor of pharmaceutical products in China."

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company which discovers, develops, and distributes over 2,300 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine ("TCM") products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces, over 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

    For more information, please contact:

    Company Contact:
     Ms. Huizhen Yu
     Chief Financial Officer
     China Medicine Corporation
     Tel:   +1-732-438-8866
     Email: konzern08@163.com

    Investor Relations Contact:
     Mr. Crocker Coulson
     President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY Office)
     Email: crocker.coulson@ccgir.com

'/>"/>
SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSD Bio Group, LLC chosen by U.S.-China Economic & Security Review Commission for Report on Chinas High Tech Sectors
2. China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
3. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
4. China Biologic Products Reports Strong Third Quarter 2008 Results
5. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
6. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
7. China Biologic Products Announces Third Quarter 2008 Results Conference Call
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. China Clean Energy Resumes Biodiesel Production After Temporary Halt
10. China Medicine Announces Conference Call to Discuss Third Quarter 2008 Results
11. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
(Date:6/22/2016)...  According to Kalorama Information, the dominant trends ... include significant efforts in automation as well as ... affordable sequencers, say the healthcare market research firm, ... sample prep materials.  The healthcare market research company,s ... Next Generation Sequencing (NGS) , highlights major trends ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):